Abbvie Therapeutics India Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 8.00 Cr
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 7.86%
- Profit Growth 7.63%
- Ebitda 8.84%
- Net Worth -33.10%
- Total Assets -6.14%
About Abbvie Therapeutics India
Abbvie Therapeutics India Private Limited (ATIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 July 1994 and has a history of 30 years and seven months. Its registered office is in Bangaluru, Karnataka, India.
The Corporate was formerly known as Allergan India Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 8.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Abbvie Therapeutics India Private Limited India is Perumal Chinnaiah as COMPANY SECRETARY. Ajay Piramal, Swati Piramal, Suresh Pattathil, and Four other members serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33201KA1994PTC023162
- Company No.
023162
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 1994
- Date of AGM
11 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Abbvie Therapeutics India Private Limited offer?
Abbvie Therapeutics India Private Limited offers a wide range of products and services, including Diabetic Medicines, Vitamins, Minerals & Antioxidants.
Who are the key members and board of directors at Abbvie Therapeutics India?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Suresh Pattathil ![]() | Managing Director | 10-Jul-2020 | Current |
Perumal Chinnaiah | Company Secretary | 03-Nov-2021 | Current |
Board Members (6)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ajay Piramal ![]() | Director | 29-Sep-2015 | Current |
Swati Piramal ![]() | Director | 26-Mar-2002 | Current |
Vidhan Kedia ![]() | Director | 24-Jan-2023 | Current |
Vivek Valsaraj ![]() | Director | 22-Feb-2022 | Current |
Hong Shi ![]() | Director | 01-Feb-2024 | Current |
Kesavan Gopinath ![]() | Director | 13-Sep-2023 | Current |
Financial Performance of Abbvie Therapeutics India.
Abbvie Therapeutics India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.86% increase. The company also saw a slight improvement in profitability, with a 7.63% increase in profit. The company's net worth observed a substantial decline by a decrease of 33.1%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Abbvie Therapeutics India?
In 2023, Abbvie Therapeutics India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)

There are no open charges registered against the company as per our records.
How Many Employees Work at Abbvie Therapeutics India?
Abbvie Therapeutics India has a workforce of 386 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Abbvie Therapeutics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abbvie Therapeutics India's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.